GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,742 DKK | +1.34% |
|
-2.71% | -19.14% |
| Jun. 28 | Would you like some more inflation? |  |
| Jun. 28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
Presenter SpeechRajan Sharma (Analysts)Good morning, everyone. Thanks for joining. My name is ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-08-01
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,720
DKK
Average target price
2,464
DKK
Spread / Average Target
+43.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.14% | 15.71B | |
| +15.58% | 122B | |
| +16.60% | 113B | |
| +17.55% | 26.22B | |
| -24.33% | 19.01B | |
| -17.95% | 15.22B | |
| -46.81% | 14.72B | |
| +58.78% | 14.58B | |
| +4.91% | 13.84B | |
| +100.06% | 10.4B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09
